Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases

Reuters

2025/11/10

<a href="https://laohu8.com/S/GLUE">Monte Rosa Therapeutics</a> Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases

Monte Rosa Therapeutics Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571686-en) on November 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582810889"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582810889\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582810889?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582810889","market":"fut","top_or_hot":-1,"title":"Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571686-en) on November 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571686-en) on November 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1QvLpm:1","article_id":"2582810889","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582810889","pubTimestamp":1762740521,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Monte Rosa Therapeutics Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","BK4588":"碎股","GLUE":"Monte Rosa Therapeutics","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4539":"次新股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Monte Rosa Therapeutics宣布NEK7降解剂MRT-8102治疗心血管疾病的1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"GLUE":0.9},"content_text":"Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases\n    \n\n        Monte Rosa Therapeutics Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571686-en) on November 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}